Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase
Illumina Inc's (NASDAQ: ILMN) Grail Inc acquisition is reportedly in more hot water when Grail mistakenly sent form letters to 400 patients, suggesting they may have developed cancer.
Blood glucose levels reduced by 19.9% with DehydraTECH-CBDImprovements in kidney function also demonstratedKELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or